May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
Synthesis and Characterization of a Novel Class of Thiol Reducing Agents Which Are Highly Neuroprotective for Retinal Ganglion Cells
Author Affiliations & Notes
  • C.R. Schlieve
    Department of Ophthalmology and Visual Sciences, University of Wisconsin Medical School, Madison, WI
  • B.L. Nilsson
    Department of Chemistry,
    University of Wisconsin, Madison, WI
  • R.T. Raines
    Departments of Biochemistry and Chemistry,
    University of Wisconsin, Madison, WI
  • L.A. Levin
    Department of Ophthalmology and Visual Sciences, University of Wisconsin Medical School, Madison, WI
  • Footnotes
    Commercial Relationships  C.R. Schlieve, None; B.L. Nilsson, None; R.T. Raines, Wisconsin Alumni Research Foundation P; L.A. Levin, Wisconsin Alumni Research Foundation P.
  • Footnotes
    Support  NIH EY12492, Retina Research Foundation, and Research to Prevent Blindness
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 188. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      C.R. Schlieve, B.L. Nilsson, R.T. Raines, L.A. Levin; Synthesis and Characterization of a Novel Class of Thiol Reducing Agents Which Are Highly Neuroprotective for Retinal Ganglion Cells . Invest. Ophthalmol. Vis. Sci. 2005;46(13):188.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: We previously demonstrated that shifting the retinal ganglion cell redox state towards mild reduction and preventing thiol oxidation is neuroprotective in dissociated mixed retinal cultures in vitro and optic nerve crush in vivo. We synthesized novel modifications of the thiol reductant tris(2–carboxyethyl)phosphine (TCEP) with increased cell permeability and improved chemical stability, and tested their ability to increase RGC survival at varying concentrations. Methods: Retinal ganglion cells of postnatal day 2–4 Long Evans rats were retrogradely labeled with 4',6–diamidino–2–phenylindole (DAPI). At postnatal days 11–13 the animals were sacrificed by decapitation, the retinas enzymatically dissociated, and plated on poly–L–lysine–coated 96–well flat–bottomed tissue culture plates for 3 and 6 days in Neurobasal–A, B27 supplement lacking antioxidants, and one of 3 TCEP compounds (TCEP, TCEP–BX1, and TCEP–BX2) or 3 phosphino compounds. Viable DAPI–positive RGCs were identified by calcein–AM staining. Results: At 72 hours, TCEP–BX1 was effective at rescuing acutely axotomized RGCs at concentrations from 1 nM – 100 µM. RGC survival with 1 nM TCEP–BX1 was 173 ± 12% of control (p=0.002). At 144 hours, TCEP–BX1 rescued RGCs at concentrations from 10 pM – 1 µM. Another compound, TCEP–BX2 rescued RGCs at 10 pM (177 ± 20%; p=0.006) and 10 nM (251 ± 34%; p=0.004) at 3 days. Conclusions: Modified cell permeable thiol reductants are effective neuroprotectants for retinal ganglion cells at picomolar concentrations.

Keywords: ganglion cells • neuroprotection • pharmacology 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×